Dionysus Healthcare
Dionysus Health is a molecular diagnostics company focused on maternal mental health. We recognize there is always an anxious patient waiting—and that the consequences of postpartum depression are devastating: it contributes to 1 in 4 maternal deaths, 23% of affected women receive no treatment, and the U.S. spends over $17B annually on its fallout. To address this crisis, we developed myLuma™, the first prenatal blood test that predicts a woman’s risk of postpartum depression as early as 28 weeks pregnant. Our mission is to replace delayed, self-reported screenings with clinically validated diagnostics that deliver reliable, early insights for patients, providers, and health systems—transforming maternal care through precision and prevention.
Dionysus Healthcare
Dionysus Health is a molecular diagnostics company focused on maternal mental health. We recognize there is always an anxious patient waiting—and that the consequences of postpartum depression are devastating: it contributes to 1 in 4 maternal deaths, 23% of affected women receive no treatment, and the U.S. spends over $17B annually on its fallout. To address this crisis, we developed myLuma™, the first prenatal blood test that predicts a woman’s risk of postpartum depression as early as 28 weeks pregnant. Our mission is to replace delayed, self-reported screenings with clinically validated diagnostics that deliver reliable, early insights for patients, providers, and health systems—transforming maternal care through precision and prevention.
